Fanning the flames of tumor growth: Enzyme responsible for protecting chromosome ends stimulates tumorigenesis

February 27, 2013
Fanning the flames of tumor growth: Enzyme responsible for protecting chromosome ends stimulates tumorigenesis
Tumor cells forced to overexpress telomerase (left) are prone to increased growth and colony formation. This can be reversed by reducing expression of NF-κB (right). Credit: 2012 A. Ghosh et al.

Chromosomes are capped by long, repetitive DNA sequences called telomeres. These caps prevent genomic damage by insulating against the steady shortening of DNA ends that naturally accompanies replication. Once mature, cells generally stop producing the telomere-building enzyme telomerase and stop dividing when these caps have shortened to a critical length. However, many cancer cells get around this restriction by restoring telomerase production, allowing uncontrolled growth.

Several studies have indicated that telomerase performs functions other than chromosome capping. Research from Vinay Tergaonkar's team at the A*STAR Institute of in Singapore has revealed how NF-κB—another protein abnormally activated in many cancers—not only stimulates release of signals that promote an to help beat back infectious threats, but can also establish physiological conditions that favor cancerous growth if left unchecked. " and telomerase reactivation are hallmarks of most human cancers," says Tergaonkar, "but the mechanism of how enhanced NF-κB and telomerase activities are each sustained in cancers is unknown."

Their experiments revealed a surprisingly close relationship between these processes. Boosting telomerase activity in cultured human cancer cells enhanced tumorigenesis, but these effects could be countered by forcing cells to produce lower levels of NF-κB. The researchers subsequently demonstrated that telomerase directly enhances NF-κB activity (see image), and found that genetically modified mice lacking telomerase showed a greatly reduced inflammatory response following exposure to bacterial toxins.

Similar effects were apparent when Tergaonkar's team compared NF-κB activity in telomerase-producing and deficient cells. Since both cell lines exhibited equivalent telomere lengths, these results favor a telomere-independent mode of action. The researchers demonstrated that telomerase binds directly to numerous NF-κB target genes, and actually strengthens NF-κB's association with several of these genomic sites. For example, telomerase and NF-κB collaboratively stimulate production of the major inflammatory signal interleukin-6 (IL-6). Tergaonkar and co-workers also showed that a chemical inhibitor of telomerase dramatically reduced IL-6 production in a wide variety of leukemia cell lines.

Perhaps most importantly, the gene encoding telomerase is itself a target of NF-κB, creating a 'vicious circle' of signaling. "The two pathways fuel each other's activities," says Tergaonkar. "These findings hence provide a unifying mechanism for the sustained inflammation seen in a vast majority of cancers, and identify telomerase as a novel regulator of inflammation." In future efforts, his team will explore how telomerase exerts its gene regulatory effects and seek out potential partner molecules that assist in this process.

Explore further: Scientists identify potential drug target for inflammatory diseases including cancers

More information: Ghosh, A., Saginc, G., Leow, S. C., Khattar, E., Shin, E. M. et al. Telomerase directly regulates NF-κB-dependent transcription. Nature Cell Biology 14, 1270–1281 (2012). www.nature.com/ncb/journal/v14 … 12/full/ncb2621.html

Related Stories

Scientists identify potential drug target for inflammatory diseases including cancers

November 21, 2012
A*STAR scientists have identified the enzyme, telomerase, as a cause of chronic inflammation in human cancers. Chronic inflammation is now recognized as a key underlying cause for the development of many human cancers, autoimmune ...

Research reveals how cancer-driving enzyme works

May 6, 2011
Cancer researchers at UT Southwestern Medical Center are helping unlock the cellular-level function of the telomerase enzyme, which is linked to the disease's growth.

Scientists capture single cancer molecules at work

December 8, 2011
Researchers have revealed how a molecule called telomerase contributes to the control of the integrity of our genetic code, and when it is involved in the deregulation of the code, its important role in the development of ...

New point of focus found for the treatment of rheumatoid arthritis and other autoimmune diseases

October 9, 2012
Scientists affiliated with VIB and UGent have discovered a mechanism used by the protein A20 to combat inflammation. This could be a very important point of focus in the search for a treatment for autoimmune diseases such ...

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.